Henry Schein Beheer

Beheer criteriumcontroles 3/4

De CEO Henry Schein is Stan Bergman, benoemd in Jan1989, heeft een ambtstermijn van 35.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.01M, bestaande uit 16.2% salaris en 83.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.6% van de aandelen van het bedrijf, ter waarde $ 55.53M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.8 jaar en 12.3 jaar.

Belangrijke informatie

Stan Bergman

Algemeen directeur

US$10.0m

Totale compensatie

Percentage CEO-salaris	16.2%
Dienstverband CEO	35.8yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	8.8yrs
Gemiddelde ambtstermijn bestuur	12.3yrs

Recente managementupdates

Recent updates

Henry Schein: Another Day, Another Purchase

Nov 20

Henry Schein's (NASDAQ:HSIC) Conservative Accounting Might Explain Soft Earnings

Nov 13

There Are Reasons To Feel Uneasy About Henry Schein's (NASDAQ:HSIC) Returns On Capital

Apr 14

Despite Disappointing Results, Henry Schein Looks Appealing Moving Forward

Feb 28

Is Henry Schein (NASDAQ:HSIC) A Risky Investment?

Oct 11

Is There Now An Opportunity In Henry Schein, Inc. (NASDAQ:HSIC)?

Sep 23

Is There An Opportunity With Henry Schein, Inc.'s (NASDAQ:HSIC) 49% Undervaluation?

Aug 21

Henry Schein (NASDAQ:HSIC) Might Be Having Difficulty Using Its Capital Effectively

Aug 01

These 4 Measures Indicate That Henry Schein (NASDAQ:HSIC) Is Using Debt Reasonably Well

Jul 09

At US$74.94, Is Henry Schein, Inc. (NASDAQ:HSIC) Worth Looking At Closely?

Jun 09

Are Investors Undervaluing Henry Schein, Inc. (NASDAQ:HSIC) By 36%?

May 21

Henry Schein (NASDAQ:HSIC) Hasn't Managed To Accelerate Its Returns

May 01

Here's Why Henry Schein (NASDAQ:HSIC) Can Manage Its Debt Responsibly

Apr 10

Estimating The Intrinsic Value Of Henry Schein, Inc. (NASDAQ:HSIC)

Feb 15

Returns On Capital At Henry Schein (NASDAQ:HSIC) Have Stalled

Jan 28

These 4 Measures Indicate That Henry Schein (NASDAQ:HSIC) Is Using Debt Reasonably Well

Jan 10

Is There Now An Opportunity In Henry Schein, Inc. (NASDAQ:HSIC)?

Dec 11

Is There An Opportunity With Henry Schein, Inc.'s (NASDAQ:HSIC) 43% Undervaluation?

Nov 04

Buy Henry Schein To Receive 'Resiliency Premium' In Equity Portfolios

Aug 25

Henry Schein announces $400M increase to stock buyback plan

Aug 18

Analyse CEO-vergoeding

Hoe is Stan Bergman's beloning veranderd ten opzichte van Henry Schein's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 28 2024	n/a	n/a	US$314m
Jun 29 2024	n/a	n/a	US$352m
Mar 30 2024	n/a	n/a	US$388m
Dec 30 2023	US$10m	US$2m	US$416m
Sep 30 2023	n/a	n/a	US$445m
Jul 01 2023	n/a	n/a	US$458m
Apr 01 2023	n/a	n/a	US$478m
Dec 31 2022	US$8m	US$2m	US$538m
Sep 24 2022	n/a	n/a	US$638m
Jun 25 2022	n/a	n/a	US$650m
Mar 26 2022	n/a	n/a	US$646m
Dec 25 2021	US$11m	US$2m	US$631m
Sep 25 2021	n/a	n/a	US$626m
Jun 26 2021	n/a	n/a	US$606m
Mar 27 2021	n/a	n/a	US$438m
Dec 26 2020	US$6m	US$751k	US$403m
Sep 26 2020	n/a	n/a	US$591m
Jun 27 2020	n/a	n/a	US$585m
Mar 28 2020	n/a	n/a	US$713m
Dec 28 2019	US$14m	US$1m	US$701m
Sep 28 2019	n/a	n/a	US$488m
Jun 29 2019	n/a	n/a	US$444m
Mar 30 2019	n/a	n/a	US$438m
Dec 29 2018	n/a	n/a	US$431m
Sep 29 2018	n/a	n/a	US$304m
Jun 30 2018	n/a	n/a	US$352m
Mar 31 2018	n/a	n/a	US$377m

Compensatie versus markt: De totale vergoeding ($USD 10.01M ) Stan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 7.94M ).

Compensatie versus inkomsten: De beloning van Stan is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Stan Bergman (74 yo)

35.8yrs

Tenure

US$10,005,729

Compensatie

Mr. Stanley M. Bergman, also known as Stan, has been the Chief Executive Officer and Executive Chairman of Henry Schein, Inc. since 1989 and has been its Executive Director since 1982. Mr. Bergman served a...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Stanley Bergman	Executive Chairman & CEO	35.8yrs	US$10.01m	0.60% $ 55.5m
James Breslawski	President	19.5yrs	US$2.69m	0.11% $ 10.5m
Ronald South	Senior VP & CFO	2.6yrs	US$2.35m	0.0080% $ 732.7k
Michael Ettinger	Executive VP & COO	2.3yrs	US$2.97m	0.081% $ 7.4m
Mark Mlotek	Executive VP	12.8yrs	US$3.22m	0.075% $ 6.9m
Olga Timoshkina	VP of Corporate Finance	3.2yrs	geen gegevens	geen gegevens
Christopher Pendergast	Senior VP & CTO	6.6yrs	geen gegevens	geen gegevens
Graham Stanley	VP of Investor Relations & Strategic Finance Project Officer	no data	geen gegevens	geen gegevens
Walter Siegel	Senior VP & Chief Legal Officer	11.1yrs	geen gegevens	0.032% $ 2.9m
Ann Gothard	Vice President of Global Corporate Media Relations	no data	geen gegevens	geen gegevens
Christine Sheehy	Senior VP & Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
Gerard Meuchner	Chief Global Communications Officer & VP	12.8yrs	geen gegevens	geen gegevens

8.8yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van HSIC is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stanley Bergman	Executive Chairman & CEO	42.8yrs	US$10.01m	0.60% $ 55.5m
Mark Mlotek	Executive VP	29.2yrs	US$3.22m	0.075% $ 6.9m
Philip Laskawy	Independent Lead Director	22.8yrs	US$335.40k	0.029% $ 2.7m
Joseph Herring	Independent Director	8.5yrs	US$313.00k	0.018% $ 1.6m
Louis Sullivan	Chairman of Medical Advisory Board	18.3yrs	US$260.65k	geen gegevens
Norman Matthews	Member of Medical Advisory Board	no data	US$224.35k	geen gegevens
Bradley Sheares	Independent Director	14.8yrs	US$304.20k	0.0027% $ 246.4k
Carol Raphael	Independent Director	12.3yrs	US$282.60k	0.023% $ 2.2m
Kurt Kuehn	Independent Director	8.5yrs	US$316.40k	0.0014% $ 129.6k
Deborah Derby	Independent Director	3.8yrs	US$304.80k	0.00061% $ 56.1k
Mohamad Ali	Independent Director	3.8yrs	US$271.60k	0.0061% $ 561.7k
Anne Margulies	Independent Director	6.4yrs	US$291.40k	0.016% $ 1.4m

12.3yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HSIC zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.3 jaar).

Henry Schein Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insider recently sold US$1.5m worth of stock

Insider notifies of intention to sell stock

Henry Schein, Inc. Announces Appointment of Members to the Company’S Executive Management Committee

Insider recently sold US$478k worth of stock

Henry Schein, Inc., Annual General Meeting, May 21, 2024

Henry Schein Appoints Carole T. Faig as New Independent Director

Recent updates

Henry Schein: Another Day, Another Purchase

Ananym Capital Management Pushes for Changes at Henry Schein

Ananym Capital Management Pushes for Changes at Henry Schein

Henry Schein's (NASDAQ:HSIC) Conservative Accounting Might Explain Soft Earnings

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Henry Schein, Inc. Updates Earnings Guidance for the Full Year 2024

Is Now An Opportune Moment To Examine Henry Schein, Inc. (NASDAQ:HSIC)?

Henry Schein, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Henry Schein, Inc.'s (NASDAQ:HSIC) Popularity With Investors Is Clear

Henry Schein, Inc.(NasdaqGS:HSIC) dropped from FTSE All-World Index (USD)

Price target decreased by 7.7% to US$73.27

Insider recently sold US$1.5m worth of stock

Insider notifies of intention to sell stock

Henry Schein (NASDAQ:HSIC) Will Be Hoping To Turn Its Returns On Capital Around

Consensus EPS estimates fall by 12%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

Is It Time To Consider Buying Henry Schein, Inc. (NASDAQ:HSIC)?

Henry Schein, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Market Participants Recognise Henry Schein, Inc.'s (NASDAQ:HSIC) Earnings

Henry Schein: Acquisition Strategy Isn't Pulling Its Economic Weight

Here's Why Henry Schein (NASDAQ:HSIC) Has A Meaningful Debt Burden

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

Is It Too Late To Consider Buying Henry Schein, Inc. (NASDAQ:HSIC)?

There Are Reasons To Feel Uneasy About Henry Schein's (NASDAQ:HSIC) Returns On Capital

Henry Schein, Inc. to Report Q1, 2024 Results on May 07, 2024

Henry Schein, Inc. Announces Appointment of Members to the Company’S Executive Management Committee

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority interest in TriMed, Inc.

Insider recently sold US$478k worth of stock

Henry Schein, Inc., Annual General Meeting, May 21, 2024

Despite Disappointing Results, Henry Schein Looks Appealing Moving Forward

Full year 2023 earnings: EPS misses analyst expectations

Henry Schein, Inc. Presents Comprehensive Lineup of Solutions At the 2024 Chicago Dental Society Mid Winter Meeting

Henry Schein, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire an unknown majority interest in TriMed, Inc.

Henry Schein Appoints Carole T. Faig as New Independent Director

Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Henry Schein, Inc. Provides Earnings Guidance for 2023

Henry Schein, Inc. announced delayed 10-Q filing

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority stake in Shield HealthCare, Inc.

Is Henry Schein (NASDAQ:HSIC) A Risky Investment?

Is There Now An Opportunity In Henry Schein, Inc. (NASDAQ:HSIC)?

Is There An Opportunity With Henry Schein, Inc.'s (NASDAQ:HSIC) 49% Undervaluation?

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year of 2023

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS misses analyst expectations

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire a majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired a majority stake in Large Practice Sales LLC.

Henry Schein (NASDAQ:HSIC) Might Be Having Difficulty Using Its Capital Effectively

Henry Schein, Inc. to Report Q2, 2023 Results on Aug 07, 2023

These 4 Measures Indicate That Henry Schein (NASDAQ:HSIC) Is Using Debt Reasonably Well

Insider recently sold US$835k worth of stock

At US$74.94, Is Henry Schein, Inc. (NASDAQ:HSIC) Worth Looking At Closely?

Executive Vice Chairman & President notifies of intention to sell stock

Executive VP & COO notifies of intention to sell stock

Executive VP recently sold US$1.9m worth of stock

Executive VP notifies of intention to sell stock

Are Investors Undervaluing Henry Schein, Inc. (NASDAQ:HSIC) By 36%?

Henry Schein, Inc. Provides Sales Guidance for the Fiscal Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) agreed to acquire SIN - Sistema de Implante Nacional S.A. from Southern Cross Group.

Henry Schein (NASDAQ:HSIC) Hasn't Managed To Accelerate Its Returns

Here's Why Henry Schein (NASDAQ:HSIC) Can Manage Its Debt Responsibly

Independent Director recently sold US$148k worth of stock